bioMérieux revenue and financials
€81.15Change from previous close: +1.31%Absolute change: +€1.05
In the fiscal year ended December 2025, bioMérieux reported revenue of €4.07B (+2.26% year over year). Net income was €397.5M, a net margin of 9.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +2.26%
- 2025 vs 2024
- Net income growth
- −8.03%
- 2025 vs 2024
- Net margin
- 9.8%
- 2024: 10.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|
| Total assets | 5,694 | 5,575 | 5,366 |
| Current assets | 2,595 | 2,540 | 2,277 |
| Cash and equivalents | 658 | 570 | 381 |
| Inventory | 975 | 960 | 974 |
| Net property, plant and equipment | 1,709 | 1,657 | 1,593 |
| Goodwill | 757 | 728 | 728 |
| Other intangible assets | 415 | 402 | 411 |
| Long-term investments | 0.7 | 0.7 | 0.8 |
| Current liabilities | 1,128 | 1,065 | 1,005 |
| Accounts payable | 252 | 262 | 229 |
| Long-term debt | 66.2 | 211 | 213 |
| Total debt | 422 | 461 | 507 |
| Total liabilities | 1,395 | 1,469 | 1,428 |
| Total equity (incl. minority) | 4,299 | 4,106 | 3,938 |
| Retained earnings | 226 | 398 | 161 |
| Minority interest | 2.1 | 3.9 | 4.0 |